About proqr therapeutics nv - PRQR
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.
PRQR At a Glance
ProQR Therapeutics NV
Zernikedreef 9
Leiden, Zuid-Holland 2333 CK
| Phone | 31-88-166-70-00 | Revenue | 20.45M | |
| Industry | Pharmaceuticals: Major | Net Income | -30,030,980.47 | |
| Sector | Health Technology | 2024 Sales Growth | 190.375% | |
| Fiscal Year-end | 12 / 2025 | Employees | 166 | |
| View SEC Filings |
PRQR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.156 |
| Price to Book Ratio | 2.968 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.918 |
| Enterprise Value to Sales | 4.377 |
| Total Debt to Enterprise Value | 0.18 |
PRQR Efficiency
| Revenue/Employee | 123,188.938 |
| Income Per Employee | -180,909.521 |
| Receivables Turnover | 9.743 |
| Total Asset Turnover | 0.125 |
PRQR Liquidity
| Current Ratio | 3.955 |
| Quick Ratio | 3.955 |
| Cash Ratio | 3.841 |
PRQR Profitability
| Gross Margin | 85.395 |
| Operating Margin | -164.57 |
| Pretax Margin | -147.897 |
| Net Margin | -146.855 |
| Return on Assets | -18.411 |
| Return on Equity | -43.705 |
| Return on Total Capital | -27.861 |
| Return on Invested Capital | -35.56 |
PRQR Capital Structure
| Total Debt to Total Equity | 17.54 |
| Total Debt to Total Capital | 14.922 |
| Total Debt to Total Assets | 9.248 |
| Long-Term Debt to Equity | 12.497 |
| Long-Term Debt to Total Capital | 10.632 |